Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor.
Schavgoulidze A, Talbot A, Perrot A, Cazaubiel T, Leleu X, Manier S, Buisson L, Mahéo S, Do Souto Ferreira L, Pavageau L, Hulin C, Marolleau JP, Voillat L, Belhadj K, Divoux M, Slama B, Brechignac S, Macro M, Stoppa AM, Sanhes L, Orsini-Piocelle F, Fontan J, Chretien ML, Demarquette H, Mohty M, Avet-Loiseau H, Corre J. Schavgoulidze A, et al. Among authors: brechignac s. Blood. 2023 Mar 16;141(11):1308-1315. doi: 10.1182/blood.2022017863. Blood. 2023. PMID: 36375118 Free PMC article.
Cardiac iron overload assessed by T2* magnetic resonance imaging and cardiac function in regularly transfused myelodysplastic syndrome patients.
Pascal L, Beyne-Rauzy O, Brechignac S, Marechaux S, Vassilieff D, Ernst O, Berthon C, Gyan E, Gourin MP, Dreyfus F, Fenaux P, Rose C. Pascal L, et al. Among authors: brechignac s. Br J Haematol. 2013 Aug;162(3):413-5. doi: 10.1111/bjh.12368. Epub 2013 May 9. Br J Haematol. 2013. PMID: 23656172 Free article. No abstract available.
Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA.
Fitoussi O, Belhadj K, Mounier N, Parrens M, Tilly H, Salles G, Feugier P, Ferme C, Ysebaert L, Gabarre J, Herbrecht R, Janvier M, Van Den Neste E, Morschhauser F, Casasnovas O, Ghesquieres H, Anglaret B, Brechignac S, Haioun C, Gisselbrecht C. Fitoussi O, et al. Among authors: brechignac s. Haematologica. 2011 Aug;96(8):1136-43. doi: 10.3324/haematol.2010.038109. Epub 2011 May 5. Haematologica. 2011. PMID: 21546499 Free PMC article. Clinical Trial.
Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.
Leleu X, Attal M, Arnulf B, Moreau P, Traulle C, Marit G, Mathiot C, Petillon MO, Macro M, Roussel M, Pegourie B, Kolb B, Stoppa AM, Hennache B, Bréchignac S, Meuleman N, Thielemans B, Garderet L, Royer B, Hulin C, Benboubker L, Decaux O, Escoffre-Barbe M, Michallet M, Caillot D, Fermand JP, Avet-Loiseau H, Facon T; Intergroupe Francophone du Myélome. Leleu X, et al. Among authors: brechignac s. Blood. 2013 Mar 14;121(11):1968-75. doi: 10.1182/blood-2012-09-452375. Epub 2013 Jan 14. Blood. 2013. PMID: 23319574 Free article. Clinical Trial.
Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients.
Hebraud B, Leleu X, Lauwers-Cances V, Roussel M, Caillot D, Marit G, Karlin L, Hulin C, Gentil C, Guilhot F, Garderet L, Lamy T, Brechignac S, Pegourie B, Jaubert J, Dib M, Stoppa AM, Sebban C, Fohrer C, Fontan J, Fruchart C, Macro M, Orsini-Piocelle F, Lepeu G, Sohn C, Corre J, Facon T, Moreau P, Attal M, Avet-Loiseau H. Hebraud B, et al. Among authors: brechignac s. Leukemia. 2014 Mar;28(3):675-9. doi: 10.1038/leu.2013.225. Epub 2013 Jul 29. Leukemia. 2014. PMID: 23892719 Free PMC article.
Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients.
Chretien ML, Hebraud B, Cances-Lauwers V, Hulin C, Marit G, Leleu X, Karlin L, Roussel M, Stoppa AM, Guilhot F, Lamy T, Garderet L, Pegourie B, Dib M, Sebban C, Lenain P, Brechignac S, Royer B, Wetterwald M, Legros L, Orsini-Piocelle F, Voillat L, Delbrel X, Caillot D, Macro M, Facon T, Attal M, Moreau P, Avet-Loiseau H, Corre J. Chretien ML, et al. Among authors: brechignac s. Haematologica. 2014 Jul;99(7):1236-8. doi: 10.3324/haematol.2013.098608. Epub 2014 Apr 11. Haematologica. 2014. PMID: 24727820 Free PMC article.
VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial.
Moreau P, Hulin C, Macro M, Caillot D, Chaleteix C, Roussel M, Garderet L, Royer B, Brechignac S, Tiab M, Puyade M, Escoffre M, Stoppa AM, Facon T, Pegourie B, Chaoui D, Jaccard A, Slama B, Marit G, Laribi K, Godmer P, Luycx O, Eisenmann JC, Allangba O, Dib M, Araujo C, Fontan J, Belhadj K, Wetterwald M, Dorvaux V, Fermand JP, Rodon P, Kolb B, Glaisner S, Malfuson JV, Lenain P, Biron L, Planche L, Caillon H, Avet-Loiseau H, Dejoie T, Attal M. Moreau P, et al. Among authors: brechignac s. Blood. 2016 May 26;127(21):2569-74. doi: 10.1182/blood-2016-01-693580. Epub 2016 Mar 21. Blood. 2016. PMID: 27002117 Free article. Clinical Trial.
Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome.
Royer B, Minvielle S, Diouf M, Roussel M, Karlin L, Hulin C, Arnulf B, Macro M, Cailleres S, Brion A, Brechignac S, Belhadj K, Chretien ML, Wetterwald M, Chaleteix C, Tiab M, Leleu X, Frenzel L, Garderet L, Choquet S, Fuzibet JG, Dauriac C, Forneker LM, Benboubker L, Facon T, Moreau P, Avet-Loiseau H, Marolleau JP. Royer B, et al. Among authors: brechignac s. J Clin Oncol. 2016 Jun 20;34(18):2125-32. doi: 10.1200/JCO.2015.63.1929. Epub 2016 Apr 25. J Clin Oncol. 2016. PMID: 27114594 Clinical Trial.
Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma.
Dejoie T, Corre J, Caillon H, Hulin C, Perrot A, Caillot D, Boyle E, Chretien ML, Fontan J, Belhadj K, Brechignac S, Decaux O, Voillat L, Rodon P, Fitoussi O, Araujo C, Benboubker L, Fontan C, Tiab M, Godmer P, Luycx O, Allangba O, Pignon JM, Fuzibet JG, Legros L, Stoppa AM, Dib M, Pegourie B, Orsini-Piocelle F, Karlin L, Arnulf B, Roussel M, Garderet L, Mohty M, Meuleman N, Doyen C, Lenain P, Macro M, Leleu X, Facon T, Moreau P, Attal M, Avet-Loiseau H. Dejoie T, et al. Among authors: brechignac s. Blood. 2016 Dec 22;128(25):2941-2948. doi: 10.1182/blood-2016-07-726778. Epub 2016 Oct 11. Blood. 2016. PMID: 27729323 Free PMC article. Clinical Trial.
42 results